Keytruda (pembrolizumab)
pCPA File Number:
21553
Negotiation Status:
Concluded with an LOI
Indication(s):
Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), for first-line treatment of adult patients
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0235-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: